Background--We sought to examine patient characteristics, peri-infarction invasive and pharmacologic management, and in-hospital major bleeding in myocardial infarction patients with atrial fibrillation or flutter, based on home anticoagulant use.
S
troke prevention is among the primary therapeutic goals in managing atrial fibrillation or flutter (AF). 1, 2 Clinical guidelines for AF recommend the use of long-term anticoagulant therapy, as driven by individually predicted stroke risk. 2 Approximately 7% to 10% of myocardial infarction (MI) patients and 10% to 15% of patients undergoing percutaneous coronary intervention (PCI) have a history of AF. 3, 4 Dual antiplatelet therapy (DAPT) is routine after PCI and has been shown to be superior to aspirin plus warfarin for the prevention of stent thrombosis. 5 However, warfarin is more effective than DAPT for the prevention of stroke in AF. 6 Since 2010, direct oral anticoagulants (DOACs) have been increasingly utilized for stroke prevention in AF given their advantages over warfarin. In patients with nonvalvular AF, DOACs have been associated with similar efficacy for prevention of stroke and systemic embolism and rates of bleeding and intracranial hemorrhage similar to or lower than those with warfarin. [7] [8] [9] [10] At the same time, stronger P2Y 12 inhibitors (prasugrel and ticagrelor) have proven superior to clopidogrel in preventing ischemic events and stent thrombosis in patient with acute coronary syndrome (ACS). 11, 12 Peri-infarction management of AF patients might be affected by home anticoagulant status and requires careful weighing of risks of stent thrombosis, ischemic stroke, and bleeding, which are inherently higher in the peri-infarction and periprocedural periods. [13] [14] [15] Prior studies have examined outcomes and bleeding rehospitalizations in AF patients with ACS who were treated in the era of clopidogrel and warfarin 16, 17 ; however, relatively few data exist regarding contemporary management and in-hospital outcomes of MI in AF patients taking DOACs and new P2Y 12 inhibitors. Therefore, we sought to examine patient characteristics, peri-infarction management strategies, differences in periprocedural antithrombotic and antiplatelet therapies and in-hospital outcomes, particularly in-hospital major bleeding, in MI patients with AF stratified by home anticoagulant use in the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry database from January 2015 to December 2016.
Methods

ACTION Registry
The ACTION Registry is a US quality improvement initiative for patients with MI. Participating sites enroll consecutive, unselected patients with ST-segment-elevation MI (STEMI) and non-STEMI (NSTEMI), as previously described. 18 This registry is part of a quality-improvement initiative sponsored by the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines. The ACTION Registry includes data abstraction training, data quality thresholds for inclusion, site data-quality feedback reports, independent auditing, and data validation. Auditing of data has demonstrated chart review agreement of >93% of collected variables. 19 At each participating site, the respective institutional review board approved registry participation. The requirement to obtain informed consent from the participants was waived.
Study Population
The starting analysis population (including the period when home DOAC data were collected by the ACTION Registry) comprised 293 197 MI patients from 781 US hospitals, who were cared for from January 2015 to December 2016 ( Figure 1 ). STEMI and NSTEMI cohorts were analyzed separately. Patients were then stratified into 3 groups by home anticoagulant status: (1) no anticoagulant therapy, (2) warfarin therapy, or (3) DOAC therapy. Baseline patient demographics, medical history, presentation features, concomitant pharmacotherapies, and in-hospital outcomes were examined. Patients were excluded sequentially if they had no AF or were missing information regarding AF status (n=266 653), stayed in a non-ACTION hospital for >24 hours before transfer (n=3), were missing data regarding home DOAC status (n=76), or were listed as taking both warfarin and DOAC (n=40).
Definitions and End Points
The primary outcome for our study was in-hospital major bleeding. Major bleeding was defined as any of the following criteria: (1) an absolute hemoglobin decrease ≥4 g/dL (baseline to nadir), (2) intracranial hemorrhage, (3) documented or suspected retroperitoneal bleed, (4) any red cell blood transfusion with baseline hemoglobin ≥9 g/dL, or (5) any red cell transfusion with hemoglobin <9 g/dL and a suspected bleeding event. Given that most patients undergoing coronary artery bypass grafting (CABG) receive blood transfusions related to surgery, bleeding events were considered only if they occurred before CABG. 19 Patients were considered to have AF if they had any history of such
Clinical Perspective
What Is New?
• ST-segment-elevation myocardial infarction (STEMI) patients on home warfarin or direct oral anticoagulants are managed similarly to those with no anticoagulant at presentation, without a clinically significant delay in primary percutaneous coronary intervention; non-STEMI patients on home warfarin or direct oral anticoagulants are less likely to undergo urgent angiography or percutaneous coronary intervention within 24 and 48 hours of admission compared with patients without home anticoagulant.
• Home warfarin or direct oral anticoagulant use is not associated with increased risk of in-hospital major bleeding compared with no home anticoagulant in both STEMI and non-STEMI cohorts.
What Are the Clinical Implications?
• In-hospital outcomes of STEMI and non-STEMI patients with atrial fibrillation or flutter are not negatively affected by home warfarin or direct oral anticoagulant therapy despite the perceived high bleeding risk; clinicians should not delay emergent or urgent percutaneous coronary intervention when needed in anticoagulated patients.
arrhythmias before hospital arrival. Patients were considered to be on home warfarin if they were taking warfarin routinely at home and within 2 weeks of hospitalization. Patients were considered to be on DOACs if they were on dabigatran, rivaroxaban, or apixaban routinely at home and within 2 weeks of hospitalization. Data on edoxaban use were not collected in the ACTION Registry. The frequency of primary PCI was higher in anticoagulant patients, whereas those with no home anticoagulant were more likely to receive thrombolytic therapy (Table 1 , Figure 2). The rate of diagnostic angiography was similarly high (>98%) among the 3 anticoagulant groups, with %97% of patients undergoing diagnostic angiography within 24 hours. Among the primary PCI cohort, overall door-to-balloon times were slightly longer for those on warfarin or DOACs versus no home anticoagulant (median 59 or 58 minutes versus 56 minutes; P<0.01). Radial PCI was used in 26.1% of primary PCI, with higher frequency of radial PCI in those on home warfarin or DOACs (32.8% warfarin or 32.2% DOACs versus 23.5% with no anticoagulant; P<0.01). Bare metal stents were used more frequently in warfarin or DOACs patients compared with those with no anticoagulant.
Patients presenting with no home anticoagulant were more likely to receive unfractionated heparin, low-molecular-weight heparin, or glycoprotein IIb/IIIa agents during hospitalization ( Figure 3 ). In the overall STEMI cohort, those on home warfarin or DOACs were less likely to receive prasugrel or ticagrelor within the first 24 hours compared with those with no home anticoagulant. Among those receiving primary PCI, 98% received aspirin and 93% received one of the P2Y 12 inhibitors within 24 hours of hospitalization, with similar rates of aspirin and P2Y 12 administration among the 3 groups; however, similar to the overall STEMI cohort, primary PCI patients on warfarin or DOACs were less likely to receive prasugrel or ticagrelor (Table S1 ). Figure 2 ). Overall, 32% of PCIs were performed radially, with greater frequency of radial PCI in those admitted on warfarin or DOACs than those not on home anticoagulant (33.9% warfarin, 36.0% DOACs, 30.6% no anticoagulant; P<0.01).
Patients with no home anticoagulant were more likely to be treated with unfractionated or low-molecular-weight heparin during hospitalization (Figure 4) . Utilization of glycoprotein IIb/IIIa agents was low overall (5%), with less utilization by those on home warfarin or DOACs. In the NSTEMI cohort, clopidogrel was used in 33.2%, prasugrel in 1.9% and ticagrelor in 6.9% of patients within the first 24 hours (Table 2) . Among the NSTEMI cohort undergoing an invasive strategy, aspirin, clopidogrel, prasugrel, and ticagrelor were administered more often within the first 24 hours in those with no home anticoagulant compared with those on home anticoagulants (Table S2 ).
In-Hospital Bleeding
In the STEMI cohort, 12.8% experienced major bleeding, and there were no significant differences in in-hospital major bleeding rates among the 3 groups (13.2% no anticoagulant, 12.4% warfarin, 11.2% DOACs; P=0.28; Figure 2 (Table 3) , no statistically significant association remained between in-hospital bleeding and home anticoagulant status in the STEMI cohort. Among patients on home anticoagulants, there were no differences between home warfarin and home DOACs with regard to bleeding (Table S3 ).
In the NSTEMI cohort, major bleeding occurred in 6.6% of patients, and there was a trend toward less major bleeding in those on home DOACs (6.7% no anticoagulant, 7.0% warfarin, 5.6% DOACs; P=0.05; Figure 2 ). In the NSTEMI cohort treated with an invasive strategy, there was a statistically significant difference in bleeding rates (6.0% no anticoagulant, 6.6% warfarin, 3.8% DOACs; P<0.01), whereas in the patients treated with a conservative strategy, there was a trend toward fewer bleeding events in the DOAC group (9.2% no anticoagulant, 8.0% warfarin, 6.6% DOACs; P=0.07). No differences in overall red cell transfusion or non-CABG red cell transfusion rates were observed among the 3 groups. Among NSTEMI patients on warfarin, bleeding rates were 6.4% for INR <2.0, 6.2% for INR 2.0 to 3.0, and 10.3% for INR >3.0. After multivariate adjustment for baseline differences, there was no statistically significant association between major bleeding and home anticoagulant status in the NSTEMI cohort (Table 3) . Bleeding rates were overall higher with femoral versus radial access, without significant differences in bleeding between no home anticoagulant, warfarin or DOACs within each access stratum in STEMI and NSTEMI (Table S4) .
In-Hospital Mortality
The overall in-hospital mortality in STEMI was 14.4%. There was a significant difference in all-cause mortality among the 3 home anticoagulant groups (14.9% no anticoagulant, 14.7% warfarin, 10.8% DOACs; P<0.01). After multivariate adjustment, there remained a significant difference between in-hospital mortality in STEMI, with lower mortality in the home warfarin group versus no anticoagulant and lower mortality in the DOAC group versus no anticoagulant (Table 3) . However, there were no differences between home warfarin and home DOACs regarding mortality after adjusting for patient characteristics (Table S3) .
The observed overall in-hospital mortality with NSTEMI was 5.6%, and there was a significant difference in all-cause mortality among the 3 home anticoagulant groups (6.1% no anticoagulant, 5.5% warfarin, 3.7% DOACs; P<0.01). After multivariate adjustment, there remained a significant difference between in-hospital mortality and home anticoagulant status in NSTEMI, with lower mortality in the home warfarin group versus no anticoagulant and lower mortality in the home DOAC group versus no anticoagulant (Table 3 ). There was a trend toward lower mortality favoring DOACs over warfarin after adjusting for patient characteristics (odds ratio: 0.79; 95% CI, 0.62-1.01; Table S3 ).
Other In-Hospital Outcomes
In the STEMI cohort, the rate of stroke was similar in the 3 groups (1.8% no anticoagulant, 1.2% warfarin, 1.6% DOACs; P=0.45). The mean length of stay was slightly longer in patients on home warfarin (mean: 5.0AE5.6 days with no anticoagulant, 5.4AE5.9 days with warfarin, 5.0AE5.0 days with DOACs; P=0.02). In the NSTEMI cohort, the rate of inhospital stroke was lower in those on home warfarin or DOACs (0.6% warfarin, 0.7% DOACs, 1.0% no anticoagulant; P=0.03) than those with no home anticoagulant. The length of stay was slightly longer in patients on home warfarin (mean: 5.3AE5.6 days with no anticoagulant, 5.6AE4.7 days with warfarin, 5.1AE4.7 days with DOACs; P<0.01).
Discussion
Several important and novel findings resulted from this large contemporary observational study of a national multicenter MI registry. First, 9% of patients presenting with MI have a reported history of prior AF, with the majority (>64%) not treated with home anticoagulant. Approximately 15% of AF patients presenting with MI were on one of 3 DOACs between 2015 and 2016. Second, 78% of STEMI patients are treated with primary PCI, and those on home warfarin or DOACs are managed similarly to those with no anticoagulant at presentation, without a clinically significant delay in primary PCI. In contrast, NSTEMI patients on home warfarin or DOACs are less likely to undergo urgent angiography or PCI within 24 to 48 hours of admission compared with patients without home anticoagulant. Third, home warfarin or DOAC use was not associated with increased risk of in-hospital major bleeding compared with no home anticoagulant in both STEMI and NSTEMI cohorts. Finally, home anticoagulant with warfarin and particularly with home DOAC therapy is associated with a reduced risk of in-hospital death compared with no home anticoagulant.
Unlike the STEMI cohort, the NSTEMI patients on warfarin or DOACs experienced a delay in coronary angiography or PCI and had lower utilization of angiography and PCI within 24 Continued 48 hours. A delay in coronary angiography might be reasonable for low-risk ACS patients, whereas high-risk patients might benefit from more urgent revascularization. 25 Furthermore, the lack of difference in bleeding outcomes in studies of fully anticoagulant patients 26, 27 and in our STEMI cohort suggests that urgent revascularization in fully anticoagulated NSTEMI patients on warfarin or DOACs could be safely performed.
Utilization of Anticoagulation and DOACs
DOACs have been increasingly adopted in clinical practice [28] [29] [30] because they overcome many of the limitations of warfarin therapy, including warfarin's narrow therapeutic range, drugdrug and drug-food interactions, need for frequent monitoring, delayed onset/offset, and higher bleeding risk. Clinical trials of the 4 available DOACs have demonstrated efficacy similar to warfarin (rivaroxaban or edoxaban) or improved (dabigatran or apixaban) for stroke and systemic embolism prevention and have been associated with similar (dabigatran, rivaroxaban) or lower (apixaban, edoxaban) rates of major bleeding and lower rates of intracranial hemorrhage than warfarin in patients with nonvalvular AF. [7] [8] [9] [10] 31 Given the improved safety profile of DOACs, replacing warfarin with DOACs seems reasonable, particularly in patients requiring concomitant antiplatelet therapy. In a recent meta-analysis, DOACs were more effective in reducing stroke or systemic embolism and safer with respect to the reduction of intracranial hemorrhage in nonvalvular AF patients treated with concomitant aspirin. 32 Despite this accruing evidence, our data show that DOAC utilization in the community is low in patients presenting with MI (15% of AF patients), although it is approaching that of warfarin (21% of AF patients). In fact, the majority of AF patients in this study were not on any oral anticoagulant, despite high CHA 2 DS 2 -VASc scores (mean: 4.7AE1.6). Underutilization of oral anticoagulants and leveling off of warfarin and DOACs in the community might explain a lack of decline in AF-related strokes between 2000 and 2010 seen in population studies. 33 More recent US studies have shown a promising but slow increase in anticoagulant rates since the introduction of DOACs. 28, 29 It is alarming that %65% of patients presenting with MI, despite high CHA 2 DS 2 -VASc scores, are currently not being anticoagulated in the community. Further efforts to identify AF patients, to guide proper patient selection for anticoagulants, and to expand the utilization of anticoagulants for AF are needed.
In-Hospital Bleeding
Clinical guidelines for management of MI are based on randomized trials that have largely excluded patients on chronic warfarin or DOAC therapy. 34 The clinical dilemma for AF patients requiring urgent or emergent PCI includes how to choose between acute antithrombotic therapies while carefully balancing the risks of bleeding and ischemic events. A higher risk of bleeding has been described early after MI and PCI in patients with AF on warfarin, 17, 19 whereas such data in the era of DOACs are lacking. One of our key findings is that patients with STEMI on warfarin or DOACs receive reperfusion therapy without clinically significant delay in door-to-balloon times and, importantly, without increase in in-hospital bleeding. Similarly, prior analysis of the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) registry suggested that in patients with non-STsegment-elevation ACS on home warfarin, the adjusted risk of major bleeding was similar to that of nonanticoagulated patients (odds ratio: 1.02; 95% CI, 0.93-1.11). 35 A metaanalysis of primarily observational studies suggests that coronary angiography and PCI can be safely performed on uninterrupted anticoagulation with warfarin. 26 However, prior studies of MI patients with AF lack data on frequency of subtherapeutic INR levels. 35 Notably in our study, 55% of STEMI and 43% of NSTEMI patients presenting on warfarin had INR values <2.0, which is consistent with subtherapeutic INR levels in population studies of patients on warfarin presenting to emergency departments. 27 Importantly, our data provide further insight regarding acute hemorrhagic risks in vulnerable MI patients, with novel evidence for those on home DOACs. Given the underlying concerns about 
<0.01
DOACs indicates direct oral anticoagulants; MI, myocardial infarction; NSTEMI, non-STsegment-elevation myocardial infarction; OR, odds ratio; STEMI, ST-segment-elevation myocardial infarction. *Adjusted P=0.68 for interaction between home anticoagulant and MI type. 
In-Hospital Mortality
The finding of lower in-hospital mortality in MI patients with AF on home warfarin or DOACs is intriguing and might be related to early and effective inhibition of thrombin formation with anticoagulation. In the setting of ACS, AF patients have been shown to have poorer reperfusion of the infarct-related artery compared with those without AF, potentially contributing to higher mortality among AF patients. 37 Consequently, direct and selective inhibition of factor Xa with DOACs, which target the final common pathway of the coagulation cascade as well as platelet activation, could potentially contribute to early mortality benefits. However, the observed findings of improved mortality might be secondary to anticoagulant selection bias, as well as differences in presenting characteristics (eg, frailty) and patient-specific modifications in management of fully anticoagulated patients. Among NSTEMI patients, for instance, those without home anticoagulants were more likely to present with cardiogenic shock or cardiac arrest compared with those on home anticoagulants, factors known to be associated with poor survival. In contrast, anticoagulated patients were more likely to have PCI performed via the radial access and receive fewer glycoprotein IIb/IIIa agents, factors that lead to lower in-hospital bleeding and have an impact on short-term mortality. 38, 39 Interestingly, in the non-ST-segment-elevation ACS cohort of the CRUSADE registry, anticoagulated patients had a trend toward lower adjusted odds of in-hospital mortality (odds ratio: 0.90; 95% CI, 0.80-1.02) compared with nonanticoagulated patients. 35 41, 42 Further studies would be needed to demonstrate whether significant differences exist in in-hospital outcomes in fully anticoagulated patients on warfarin or DOACs undergoing urgent invasive procedures.
Transradial Versus Transfemoral Access
As expected, clinicians modify their approach to management of anticoagulated AF patients with MI. This was noted in a recent analysis of the NCDR ACTION Registry, in which patients with AF meeting indications for anticoagulation were more likely to receive bare metal stents than drug-eluting stentspresumably because of the shorter duration of P2Y 12 inhibition required after bare metal stent. 43 Similarly, in our analysis, Multiple studies have demonstrated that the greatest benefit of transradial PCI, in terms of reduction in bleeding and vascular complications, has been observed in high-risk patients with ACS, for which, paradoxically, its utilization has been the lowest. 46 Interestingly, the lowest bleeding rates in our study were seen in those on home DOACs undergoing procedures through transradial access. The transradial approach to primary PCI in STEMI has been associated with a decrease in mortality compared with transfemoral PCI in both observational and randomized studies. 39 Prevention of access-site bleeding has been postulated to be an important mechanism through which transradial PCI reduces mortality. Wider adoption of transradial PCI in interventional practice, particularly in STEMI patients on warfarin or DOACs, presents an opportunity to potentially improve overall PCI safety and lower bleeding rates.
Limitations
Several limitations of this study should be recognized. First, data regarding provider rationale for AF treatment choices (eg, timing, type, or duration of AF; patient bleeding risk; fall risk) were lacking. Furthermore, data regarding in-hospital anticoagulant management (eg, whether warfarin or DOACs were stopped or interrupted periprocedurally) were not recorded in the database. Second, selection bias for home anticoagulant strategy and residual confounding cannot be ruled out as an explanation for some observed outcomes, particularly in-hospital mortality. Although we attempted to address this by adjusting for a broad range of patient-level clinical factors, the possibility of confounding by unmeasured covariates remains. Center at Weill Cornell Medicine had no role in the design and conduct of the study, the collection, analysis, and interpretation of the data, or the preparation, review, or approval of the manuscript.
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